Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

510
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
510
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

496
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
496
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

455
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
455
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

629
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
629
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.3K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases.

Clinical reviews in allergy & immunology·2026
Same author

Methamphetamine-associated PAH on the rise in the US: geographic trends & disparities in patient demographics and treatment strategies.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

The right kind of rarefaction: Coronary microvascular remodeling in right ventricle failure.

JHLT open·2026
Same author

IL-33-mediated mast cell and eosinophil function requires isoprenylation.

Frontiers in immunology·2025
Same author

Expert consensus on patient engagement strategies for improving patient activation and shared decision making in pulmonary arterial hypertension.

Journal of the American Association of Nurse Practitioners·2025
Same author

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: <i>Treatment Patterns and Risk Trajectories</i>.

Pulmonary circulation·2025

Related Experiment Video

Updated: Mar 12, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.

Sanjiv J Shah1, Rebecca Cogswell2, John J Ryan3

  • 1Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 600, Chicago, IL, 60611, USA. sanjiv.shah@northwestern.edu.

Current Cardiology Reports
|November 1, 2016
PubMed
Summary

Specialized heart failure with preserved ejection fraction (HFpEF) clinics can improve diagnosis and care for these complex patients. These programs are crucial for standardized treatment and increasing clinical trial enrollment for HFpEF.

Keywords:
Clinical trialsDiagnosisDisease management programHeart failure with preserved ejection fractionTreatment

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Related Experiment Videos

Last Updated: Mar 12, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Health Services Research

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a prevalent condition with significant morbidity and mortality.
  • HFpEF is often underdiagnosed and undertreated due to challenges in clinical trials and perceived lack of effective therapies.
  • Existing approaches to HFpEF management face limitations, necessitating innovative care models.

Purpose of the Study:

  • To outline the rationale and strategies for establishing dedicated clinical programs for HFpEF.
  • To detail a standardized approach for diagnosing and treating HFpEF patients within specialized clinics.
  • To discuss the operational aspects, including staffing, reimbursement, and clinical trial enrollment, for HFpEF programs.

Main Methods:

  • Pioneering the creation and implementation of specialized HFpEF clinical programs.
  • Developing systematic patient identification strategies.
  • Implementing standardized diagnostic and therapeutic protocols.
  • Validating the effectiveness of the HFpEF clinical program model.

Main Results:

  • Specialized HFpEF clinics are feasible and address the unmet need for identifying and managing these patients.
  • These programs facilitate accurate diagnosis, standardized treatment, and improved clinical trial participation.
  • The model demonstrates potential for comprehensive care delivery in HFpEF.

Conclusions:

  • Dedicated HFpEF clinical programs are essential for optimizing patient care.
  • These specialized clinics improve diagnostic accuracy, treatment standardization, and clinical trial enrollment.
  • Establishing HFpEF programs is recommended to enhance comprehensive management for complex HFpEF patients.